Analysis of the post-vaccination response in patients with relapsing multiple sclerosis treated with ofatumumab Review article

Article Sidebar

Requires Subscription PDF (Język Polski) Requires Subscription PDF


Published: Jun 30, 2024
DOI: https://doi.org/10.24292/01.MS.132300624.4
Keywords:
multiple sclerosis, SARS-CoV-2, vaccinations, ofatumumab, IgG

Main Article Content

Elżbieta Jasińska
1. Collegium Medicum, Jan Kochanowski University in Kielce. 2. Resmedica, Neurological Clinic

Abstract

The publication presents an analysis of the immune response in a patient suffering from MS, who was infected with SARS-CoV-2 during treatment with ofatumumab and was then vaccinated against COVID-19. The obtained results confirm that patients taking ofatumumab, despite long-term, complete depletion of B lymphocytes, retain immunocompetence and the course of the infection may be mild. The IgG SARS-CoV-2 antibody level was tested after contracting the disease at random times, so it is difficult to draw precise conclusions regarding the reaction to contact with the pathogen. The assessment of post-vaccination responses indicates the need to administer booster doses, which is consistent with current recommendations for vaccination against COVID-19, especially in patients treated with highly effective disease modifying therapies, including ofatumumab.

Article Details

Issue
Vol 13 No 2(47) (2024)
Section
Articles

Copyright © by Medical Education. All rights reserved.

References

1. Sormani MP, De Rossi N, Schiavetti I et al.; Musc-19 Study Group. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. Ann Neurol. 2021; 89(4): 780-9. http://doi.org/10.1002/ana.26028.
2. Wu X, Wang L, Shen L et al. Response of COVID-19 vaccination in multiple sclerosis patients following disease-modifying therapies: A meta-analysis.EBioMedicine. 2022; 81: 104102. http://doi.org/10.1016/j.ebiom.2022.104102.
3. Jasińska E. Immunocompetence after SARS-CoV-2 Infection in a Patient with Multiple Sclerosis Treated with Ofatumumab: A Case Report. Case Rep Neurol. 2022; 14(2): 320-5. http://doi.org/10.1159/000524946.
4. Hauser SL, Bar-Or A, Cohen JA et al.; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020; 383(6): 546-57. http://doi.org/10.1056/NEJMoa1917246.
5. Charakterystyka Produktu Leczniczego. Kesimpta
6. Hauser SL, Kappos L, Bar-Or A et al. The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment. Neurol Ther. 2023; 12(5): 1491-515. http://doi.org/10.1007/s40120-023-00518-0.
7. Napiórkowska-Baran K, Kołtan S, Zalewska J et al. Oznaczanie przeciwciał w codziennej prakty-ce. Część I – właściwości przeciwciał. Alergia Astma Immunologia. 2019; 24(2): 51-8.
8. Cross AH, Delgado S, Habek M et al. COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab. Neurol Ther. 2022; 11: 741-58. https://doi.org/10.1007/s40120-022-00341-z.
9. Ziemssen T, Groth M, Ettle B et al. Immune Response to SARS-CoV-2 mRNA Vaccines in an Open-Label Multicenter Study in Participants with Relapsing Multiple Sclerosis Treated with Ofatumumab. Vaccines (Basel). 2022; 10(12): 2167. http://doi.org/10.3390/vaccines10122167.
10. Jasińska E, Habek M, Wynn D et al. Impact of Ofatumumab on Immune Responses Post-vaccination in RMS Patients: ALITHIOS Vaccination Sub-study Design. Oral Presentation OPR-207 at the 7th Congress of the European Academy of Neurology, June 19-22, 2021.
11. Ziemssen T, Schlegel E, Groth M et al. Results on SARS-CoV-2 mRNA Vaccine Booster from an Open-Label Multicenter Study in Ofatumumab-Treated Participants with Relapsing Multiple Sclerosis. Vaccines (Basel). 2023; 11(5): 978. http://doi.org/10.3390/vaccines11050978.
12. Beard K, Sriwastava S. Insight in booster COVID-19 vaccine and disease modifying therapy in multiple sclerosis. J Neurol Sci. 2021; 430: 120034. http://doi.org/10.1016/j.jns.2021.120034.